The aim of this study was to assess the effect of valsartan addition to amlodipine on ankle foot volume (AFV) and pretibial subcutaneous tissue pressure (PSTP), two objective measures of ankle oedema. After a 4-week placebo period, 80 grade 1-2 hypertensive patients (diastolic blood pressure (DBP)490 mm Hg and o110 systolic blood pressure (SBP)4140 mm Hg) were randomized to amlodipine 10 mg or valsartan 160 mg or amlodipine 10 mg plus valsartan 160 mg for 6 weeks according to an open-label, blinded end point, crossover design. At the end of the placebo period and of each treatment period, blood pressure, AFV and PSTP were evaluated. AFV was measured using the principle of water displacement. PSTP was assessed connecting the subcutaneous pretibial interstitial environment with a water manometer. Both amlodipine and valsartan monotherapy significantly reduced SBP (À16.9 and -14.5 mm Hg, respectively, Po0.01 vs baseline), and DBP (À12.9 and À10.2 mm Hg, respectively, Po0.01 vs baseline) but the reduction was greater with the combination (À22.9 mm Hg for SBP, Po0.01 vs monotherapy; À16.8 mm Hg for DBP, Po0.01 vs monotherapy). Amlodipine monotherapy significantly increased both AFV ( þ 23%, Po0.01 vs baseline) and PSTP ( þ 75.5%, Po0.001 vs baseline) whereas valsartan monotherapy did not influence them. As compared to amlodipine alone, the combination produced a less marked increase in AFV ( þ 6.8%, Po0.01 vs amlodipine) and PSTP ( þ 23.2%, Po0.001 vs amlodipine). Ankle oedema was clinically evident in 24 patients with amlodipine and in six patients with the combination. These results suggest that angiotensin receptor blockers partially counteract the microcirculatory changes responsible for calcium channel blockers induced oedema formation.
Introduction
Ankle oedema is one of the most frequent side effects of antihypertensive therapy with calcium channel blockers (CCB), particularly the dihydropyridine ones. It occurs in 1-15% of patients treated with these drugs and may result in the need for dose reduction or treatment withdrawal, both of which can adversely influence antihypertensive efficacy. [1] [2] [3] The mechanisms underlying CCB-induced oedema, although not completely understood, possibly include: (a) an increase in capillary hydrostatic pressure, with consequent transcapillary fluid loss, that results from a relatively more pronounced vasodilation in precapillary than postcapillary resistance vessels; [4] [5] [6] (b) an interference with the local vascular control, probably the myogenic component, that operates to protect dependent vascular regions from increased fluid filtration. [7] [8] With any form of oedema, most physicians add a diuretic to the antihypertensive treatment. Unfortunately, diuretics, either loop or thiazide, have little effect on CCB-induced oedema because they merely decrease fluid retention but do not affect the vasodilatory mechanism of the oedema, which is predominant with CCB. 6 By contrast, adding an angiotensin-converting enzyme inhibitor (ACE-I) to the treatment with a CCB has been shown to reduce the incidence and the entity of ankle oedema. [9] [10] [11] [12] [13] The mechanisms by which ACE-I attenuate the CCBinduced oedema are not clear, but their ability to dilate venous capacitance vessels seems to play a major role by normalizing intracapillary pressure and reducing fluid exudation from the intracapillary space into the interstitium. 6, 14 Whether this ability is peculiar of ACE-I or extends to the other drugs interfering with the renin-angiotensin-aldosterone system (RAAS), that is the angiotensin receptor blockers (ARB), remains to be established. To date, to our knowledge there are no data about the effects of the addition of these drugs to CCBs on oedema formation.
The aim of the present study was to evaluate objectively whether the addition of an ARB, valsartan, to the dihydropyridine CCB amlodipine can attenuate ankle oedema formation in hypertensive patients treated for 6 weeks. To this purpose, we measured both ankle foot volume (AFV) and pretibial subcutaneous tissue pressure (PSTP), two parameters that are differently related to tissue integrity and elasticity and thus provide complementary informations on the potential for oedema formation of the drugs studied.
Patients and methods
This was a prospective, randomized, open-label, blinded-end point (PROBE), 15 crossover study.
Study population
Male and female outpatients, aged 30-75 years, with uncomplicated grade 1-2 16 essential hypertension (diastolic blood pressure (DBP)490 and o110 mm Hg and systolic blood pressure (SBP)4 140 mm Hg after 4-week placebo period) were eligible. Exclusion criteria were evidence of significant cardiac, renal, hepatic, endocrine or haematologic disease, pregnancy, known hypersensitivity to the drugs used in the study. Also patients with signs of venous insufficiency were excluded. None of the female patients were using oral contraceptives, which are known to affect subcutaneous tissue pressure and water retention.
Study protocol
At the end of an initial 4-week wash-out period, during which any eventual antihypertensive drug was discontinued and placebo was administered, patients fulfilling the inclusion criteria were randomly treated with amlodipine 10 mg OD or valsartan 160 mg OD or amlodipine 10 mg plus valsartan 160 mg OD, each given once daily at the same hour in the morning (approximately at 0800) for 6 weeks in three crossover periods each separated by a 2-week placebo period.
Patients were checked at the end of the placebo wash out period and at the end of each active treatment period. At each visit, clinic blood pressure (BP), heart rate (HR), AFV and PSTP were evaluated. BP was measured in the morning before daily drug intake (i.e. 24 h after dosing, at trough) by using a standard mercury sphygmomanometer (Korotkoff I and V), after the patients were seated for 5 min in a quiet room. Three consecutive measurements taken at 1 min interval were averaged and used as the clinic BP value. HR was measured by pulse palpation at the level of the radial artery.
AFV and PSTP measurements AFV was measured using the principle of water displacement. For each measurement, a Perspex (Meditec, Pavia, Italy) water bath with a 15 l maximum capacity was filled with the same quantity of water; subsequent immersion of the foot induces water displacement that equals the immersed volume. This water was collected and measured to achieve a fixed and reproducible degree of immersion of the foot and ankle, a stable chair with adjustable height was used and patients maintained a rigidly standardized seated position with the thigh horizontal and the lower leg vertical. Three successive recordings were performed within 5 min and averaged; between recordings, the foot was withdrawn from the water bath and dried carefully and the water lost by removal was replaced before the next recording. In this test, foot volume recordings proved to be highly reproducible (coefficient of variation 0.30%). PSTP was measured directly using the balancing open system, described by Lauderer 17 in 1884 and modified by Burch and Sodeman 18 in 1937 and the Malamani device, 19, 20 according to a method already described in detail in a previous paper, based on the connection of the pretibial subcutaneous environment to a water manometer. 13 Also in this test, three successive recordings were performed with a good reproducibility (coefficient of variation 0.25%).
Ethics
The study protocol was approved by the local Ethical Committee and written informed consent was obtained from each patient at the time of screening.
Statistical analysis
Data are given as means7s.d. The statistical analysis of the data was performed by the statistical analysis software (SAS) system, version 6.12 (SAS Institute, Inc., Cary, NC, USA). For SBP and DBP, the treatment effect was evaluated by PROC GLM: variability source considered were treatment and patients. The treatment effect on changes in AFV and PSTP was evaluated by non-parametric Wilcoxon's test. Spearman's rank test was also used for correlation analysis between these variables. In addition, 95% confidence intervals (CI) for mean and differences between treatments were calculated. Observed differences in data were considered significant if Po0.05.
Results
A total of 130 consecutive outpatients with grade 1-2 essential hypertension referred to the hypertension centre of our clinic were screened for eligibility. At the end of the placebo wash out period, 80 patients (38 males and 42 females), aged 30-75 years
The main results of the study are shown in Table 1 As expected, valsartan monotherapy did not affect AFV and PSTP as compared to baseline, whereas amlodipine monotherapy significantly increased both AFV ( þ 23%, Po0.01 vs baseline) and PSTP ( þ 75.5%, Po0.001 vs baseline). As compared to amlodipine alone, the valsartan þ amlodipine combination produced a significantly less pronounced increase in AFV ( þ 6.8%, Po0.05 vs baseline and o0.01 vs amlodipine), the mean difference between the two treatments being statistically significant (210 6 ml, 95% CI 69.9, 238.8) and in PSTP ( þ 23.2%, Po0,05 vs baseline and o0.01 vs amlodipine) the main differences between the two treatments being statistically significant (1.11 cm H 2 O, 95% CI 0.33, 1.18) (Figure 1 ). An inverse correlation was found between AFV and PSTP changes. With both amlodipine alone and valsartan-amlodipine combination, although to different degrees, the more pronounced increase in AFV corresponded to the less pronounced increase in PSTP and vice versa (correlation coefficients: À0.58, Po0.001 for amlodipine, À0.25 Po0.05 for valsartan-amlodipine). When the correlations between age and treatmentinduced changes in AFV and PSTP were considered (Figure 2 ), both amlodipine alone and valsartanamlodipine combination, although to a different extent, were found to produce increases in AFV that were greater with increasing age. Conversely, the increase in PSTP caused by both treatments was reduced with increasing age. No significant correlation was found between the changes in AFV and PSTP and the decrease in BP values induced by treatment with either amlodipine alone or with valsartan-amlodipine combination.
Ankle oedema was complained by or was clinically evident in 24 patients with amlodipine alone and in six patients with the valsartan-amlodipine combination.
Discussion
The results of this study demonstrated that in grade 1-2 hypertensive patients combination therapy with the ARB valsartan and the dihydropyridine CCB amlodipine significantly attenuated the increase in both AFV and PSTP, two objective measures of ankle oedema. These findings are similar to previous observations with the ACE-I/CCB combination, both based on spontaneously reported side effects in clinical trials [9] [10] [11] [12] and also on the use of the water displacement technique. 13, 14 The mechanisms by Valsartan-amlodipine combination and ankle oedema R Fogari et al which ARB may attenuate the CCB-induced oedema are not clear but possibly resemble those hypothesized for ACE-I. [4] [5] [6] [7] [8] Thus, RAAS blockade by both ACE-I and ARB is likely to result in venous capacitance vessels vasodilation with consequent intracapillary pressure normalization and reduced fluid exudation from the intracapillary space into the interstitium. The ability to affect the vasodilatory mechanism of the oedema produced by CCB seems to make not only ACE-I but also ARBs able to alleviate this side effect.
No correlation was found between the AFV and PSTP decrease and the reduction in BP levels produced by amlodipine monotherapy and by the valsartan/amlodipine combination. Therefore, the attenuation of extremity oedema by the combined therapy does not seem to be related to its antihypertensive effect.
In agreement with some previous findings by ourselves, 13 ,21 a different age-related response to the same stimulus for oedema formation was observed in both the amlodipine and valsartan/amlodipinetreated groups: younger patients showed the greatest increase in PSTP and the lowest increase in AFV, whereas the contrary was found in the older patients. This is probably owing to the different structural characteristics of tissues at different ages. Younger patients have greater tissue integrity and more elastic tissue components so that the trend toward fluid filtration is balanced by marked tension development in elastic tissue components with consequent increase in PSTP, which limits the AFV increase. In older patients, tissue relaxation and reduced elasticity of tissue components may produce lower tension in response to the same stimulus for oedema formation and favour fluid accumulation, with consequent greater increase in AFV than in PSTP.
No relationship was observed between the AFV and PSTP changes and other patient's characteristics like sex, body weight and hypertension duration.
From the clinical point of view, the better tolerability profile resulting from the attenuation of ankle oedema by combined valsartan/amlodipine therapy is of particular importance, because hypertension is a chronic disorder that needs long-term treatment and patient compliance.
Furthermore, combination therapy with valsartan plus amlodipine was significantly more effective in lowering BP values than either drug used alone, which confirms the usefulness of such type of combination in achieving targeted BP reductions. 22, 23 In conclusion, the present study indicates that, similar to what was observed when combining an ACE-I with a dihydropyridine CCB, the addition of the ARB valsartan to the CCB amlodipine is able to minimize ankle oedema formation, which suggests a role of RAAS blockade in counteracting the microcirculatory changes responsible for this common side effect of CCBs. Although further studies are needed to confirm these findings, the attenuation of lower extremity oedema represents a further support to the use of the combination of an ARB with a CCB together with better BP control and potential for organ protection provided by RAS inhibition. What is known about topic K Calcium antagonists induce ankle oedema formation [15] [16] K The combination of an angiotensin-converting enzyme inhibitor with a calcium channel blocker has been shown to reduce the incidence of ankle oedema [10] [11] [12] [13] [14] K This reduction has been quantified evaluating the changes in the ankle-foot-volume and the subcutaneous tissue pressure 14 What this study adds K The combination of an angiotensin II antagonist with a calcium channel blocker induces a significant attenuation of the ankle-foot volume and pretibial subcutaneous tissuepressure increase K The mechanisms possibly resemble those hypothesized for ACE-I, that is, a venous vasodilation with consequent intracapillary pressure normalization
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